Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 180 participants.
Also called NCT04287387
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 180 participants
- Registry
-
NCT04287387
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT04287387. Randomized; no masking; primary purpose treatment. Start 2020-03-02 (anticipated); primary completion 2021-03-02 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents
- Condition
- Type2 Diabetes Mellitus
- Intervention (Drug)
- Glucophage 500Mg Tablet
- Intervention (Drug)
- Acarbose Tablets
- Intervention (Drug)
- Sitagliptin tablet
- Intervention (Drug)
- Dapagliflozin Tablet
- Intervention (Drug)
- Pioglitazone Tablets
- Intervention (Drug)
- Glimepiride Tablets
- Lead sponsor
- Peking Union Medical College Hospital
- Collaborator
- Chinese Academy of Sciences
Record details
- Record id
cardio:ct-nct04287387- Content hash
5abf600c6a029e9a454c211d90744db24b8bcebe2e8cb2f3cb29e9db66a77f94